We recently compiled a list of the 12 Hot Stocks to Buy According to Analysts. In this article, we are going to take a look ...

Shares of Zai Lab rocketed to a 16-month high Thursday after the Chinese biotech posted "impressive" results for its lung cancer treatment. Please watch the video at Investors.com - The Cell ...

The consensus price target hints at a 95.6% upside potential for Zai Lab Limited (ZLAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

The FDA has granted orphan drug designation (ODD) to Zai Lab’s ZL-1310, aimed at treating small cell lung cancer (SCLC).

Zai Lab Limited (ZLAB) announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation or ODD to ZL-1310, a ...

In this article, we are going to take a look at where Zai Lab Limited (NASDAQ:ZLAB) stands against Andreas Halvorsen’s other long-term stock picks. Andreas Halvorsen is a prominent Norwegian ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that China’s National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for KarXT for the treatment of ...

Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Zai Lab in a note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst L. Chen forecasts that the ...

NovoCure and Zai Lab report PANOVA-3 trial success with TTFields therapy, achieving significant survival benefits for pancreatic cancer patients. Zai Lab shares are trading higher by 4% during ...

SHANGHAI & SUZHOU, China & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced a new strategic collaboration and worldwide license agreement with MediLink ...

Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders ...

Shares of Zai Lab Limited Unsponsored ADR (ZLAB) have gained 1.4% over the past four weeks to close the last trading session at $26.84, but there could still be a solid upside left in the stock if ...